For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesJuly 2015
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions and individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives and other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.

Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213


Seventy-Six Cancer Centers Join Forces for Cures Act
In a strong show of support for H.R. 6, the 21st Century Cures Act, 76 AACI cancer centers signed a letter to House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Ranking Member Diana DeGette (D-CO), thanking them for their efforts on 21st Century Cures. The cancer centers expressed their support for the bipartisan way that Upton and DeGette united to improve and expedite the discovery, development, and delivery of care. more...

Abstracts Selected for 7th Annual AACI CRI Meeting

The AACI Clinical Research Initiative Steering Committee has selected three abstracts from the 19 considered for judging at the 7th Annual AACI CRI Meeting, July 8-9, in Chicago. The winning abstract authors represent a collaboration between University of Kansas Cancer Center and American Society of Clinical Oncology, University of Michigan Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.

The steering committee would like to thank everyone who submitted an abstract. The concepts demonstrated that creative and thoughtful methods are being employed at the cancer centers to address clinical trial issues. All submitted abstracts can be viewed here. more...

New Director at University of Florida Health Cancer Center
Jonathan Licht, MD, is the new director of the University of Florida Health Cancer Center. Dr. Licht will start Oct. 1 and will succeed Paul Okunieff, MD. After five years as director of the Cancer Center, Dr. Okunieff will continue as chairman of the radiation oncology department. Dr. Licht, 58, joins UF in the midst of a state-supported effort to obtain National Cancer Institute designation as one of the top research centers in the country. more...

Levine Appointed AACI Government Relations Chair-Elect
Anne Levine, Vice President of External Affairs at Dana-Farber Cancer Institute, has been appointed Chair-Elect of the AACI Government Relations Forum Steering Committee. She will serve as Chair-Elect until June of 2016. Ms. Levine will succeed AACI's current Government Relations Forum Steering Committee Chair, Lisa Damiani, of Roswell Park Cancer Institute, who was appointed Chair in 2012.

The AACI Government Relations Forum meets in-person twice annually and the AACI Government Relations Forum Steering Committee holds conference calls throughout the year. To participate in the AACI Government Relations Forum please contact Jennifer Pegher, government relations manager. more...

Anne Levine (top), Lisa Damiani

AACI Physician Clinical Leadership Initiative 3rd Annual Meeting
In response to rapid changes in healthcare delivery and the expectation to "do more with less", AACI has created a forum for physician leaders responsible for overseeing clinical operations at cancer centers. This forum aims to be a resource for creating "best practices" to assist physician leaders in addressing challenges like clinical services reimbursement, quality care and patient satisfaction, integrating electronic medical records with other cancer center information technology, assimilating clinical research and clinical programs to increase trial accrual and developing performance metrics. More information about the AACI Physician Clinical Leadership Initiative can be found at

To help advance this forum, AACI invites the physician leaders responsible for cancer center clinical operations to attend an in-person meeting at the 2015 AACI/CCAF Annual Meeting at the Mandarin Oriental, Washington DC, on Sunday, October 25, 2015 from 4:00-6:00 PM, EDT. Register now! more...

Register Today for the 2015 AACI/CCAF Annual Meeting
The 2015 AACI/CCAF Annual Meeting will be held in Washington, DC, October 25-27. Information on the meeting, including the program and electronic registration is available on the AACI website. more...
News from the Centers
Awards & Honors
Ley Chosen for National Cancer Advisory Board
Siteman Cancer Center
Timothy Ley, MD, a hematologist, oncologist and cancer biologist at Washington University School of Medicine and Siteman Cancer Center, has been named to the National Cancer Advisory Board. His appointment was announced June 18 by President Barack Obama. The board advises the U.S. Secretary of Health and Human Services, the director of the National Cancer Institute (NCI) and the president on the nation’s cancer program and reviews proposals awarded by the NCI. more...
Halabi Named ASA Fellow
Duke Cancer Institute
Susan Halabi, PhD, professor of Biostatistics and Bioinformatics, was named in June a Fellow of the American Statistical Association (ASA), the nation's preeminent professional statistical society. Halabi received her PhD in 1994 from the University of Texas Health and Sciences Center, in Houston, Texas. She is the co-editor of Oncology Clinical Trials, a book whose proceeds are donated to Conquer Cancer Foundation, a non-profit fund for young investigators. more...
European Inventor Award in SMEs Category Goes to Van't Veer
UCSF Helen Diller Family Comprehensive Cancer Center
Laura Van't Veer, PhD, co-leader of the UCSF Helen Diller Family Comprehensive Cancer Center Breast Oncology Program, was awarded the prize for the invention of a gene-based tissue test which makes it possible to offer targeted treatment for breast cancer. It provides women in the early stage of breast cancer with a reliable prognosis as to whether chemotherapy is actually necessary. The technology has already helped over 40,000 women with treatment for cancer, resulting in 20 to 30 percent fewer women having to undergo lengthy chemotherapy. more...
Lassiter Recognized At 40th Anniversary Congress
Duke Cancer Institute
At its 40th Anniversary Congress last month the Oncology Nursing Society presented the Excellence in Blood and Marrow Transplantation Award to Martha E. Lassiter, RN, MSN, AOCNS, BMTCN, clinical nurse specialist, Duke Adult Bone Marrow Transplant Program. Ms. Lassiter, who joined Duke in 1983, was one of the first nurses hired in 1985 to Duke's Adult Bone Marrow Transplant Program. more...
Grants & Gifts
MSK Receives Record Gift of $150 Million for Innovative Patient Care Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering has announced the largest single gift in its history, a $150 million commitment from longtime board member David H. Koch to build a state-of-the-art outpatient medical facility that will transform cancer care. Scheduled to open in 2019, the new center will provide the most advanced cancer treatments in a dynamic space for the rapidly increasing number of patients requiring outpatient care. The 23-story building will be known as The David H. Koch Center for Cancer Care. more...
Duncan Cancer Center Receives Additional $15.9 Million in State Cancer Funding
The Dan L. Duncan Cancer Center
Researchers in the NCI-designated Dan L. Duncan Cancer Center at Baylor College of Medicine have received $15.9 million from the Cancer Prevention and Research Institute of Texas for two new large grants focused on liver cancer and prostate cancer. The newest grants bring Baylor's total CPRIT funding to more than $155 million since the agency began awarding cancer research funding in January 2010. more...
Photodynamic Therapy Center Gets $10 Million to Optimize Head, Neck Cancer Treatments
Roswell Park Cancer Institute
Roswell Park Cancer Institute has received continuation of a prestigious program project grant from the National Cancer Institute for research through the Roswell Park Photodynamic Therapy Center. The comprehensive cancer center will receive $10 million over the next five years to continue its research program on photodynamic therapy - specifically in head and neck cancers - under the direction of Sandra Gollnick, PhD. more...
Northwestern Awarded Nearly $10 Million to Study How Normal Cell Becomes Cancer Cell
The Robert H. Lurie Comprehensive Cancer Center
Northwestern University has received a five-year, $9.6 million grant from the National Cancer Institute (NCI) for a new Physical Science-Oncology Center that unites physical scientists and cancer researchers from Northwestern, the University of Chicago and University of Illinois at Chicago. The Chicago Region Physical Science-Oncology Center is part of a larger coalition assembled by the NCI to bring breakthroughs in the physical sciences to bear on the complex problem of cancer. Only four such centers have been funded across the nation this year. more...
Autophagy Defect Explored in Hereditary Breast Cancer
Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey researchers Bing Xia, PhD, and Eileen P. White, PhD, have been awarded a $2.4 million R01 grant from the National Cancer Institute to explore the relationship between the cellular-survival mechanism of autophagy and tumor suppression function in hereditary breast cancers. more...
Leadership Transitions
Zaia Named Director of Center for Gene Therapy
City of Hope Comprehensive Cancer Center
Gene therapy pioneer John A. Zaia, MD, has been named director of the Center for Gene Therapy within City of Hope's new Hematologic Malignancies and Stem Cell Transplantation Institute. Known for his research into potential gene therapy treatments for HIV, Dr. Zaia will maximize the potential of gene therapy not just for HIV, but also for cancer and other diseases as City of Hope expands its commitment to this revolutionary field of research. more...
Mesirov Appointed Associate Vice Chancellor for Computational Health Sciences
UC San Diego Moores Cancer Center
Computational biologist Jill P. Mesirov, PhD, has been appointed associate vice chancellor for computational health sciences and professor of medicine at University of California, San Diego School of Medicine and Moores Cancer Center. Dr. Mesirov most recently served as associate director and chief informatics officer at the Broad Institute of MIT and Harvard, where she directed the Computational Biology and Bioinformatics Program. more...
Fred Hutch Hires New Chief Information Officer
Fred Hutchinson Cancer Research Center
The Fred Hutchinson Cancer Research Center in Seattle has hired a new chief information officer, Matthew Trunnell, as the biomedical institution moves into an era of deep genomic sequencing and other information-heavy approaches to help find new, targeted treatments for cancer and other diseases. The institution also recently announced the hiring of a new head of licensing and commercialization, Nicole Robinson, a crucial role at a place that hopes to reap financial and not just intellectual and societal rewards from its work in cancer and immunology. more...
Prostate, Renal and Bladder Cancer Expert Joins IU Simon Cancer Center
Melvin and Bren Simon Cancer Center, Indiana University
Roberto Pili, MD, a nationally recognized expert in prostate, renal and bladder cancers, has joined the Indiana University Melvin and Bren Simon Cancer Center. Dr. Pili is the Robert Wallace Miller Professor of Oncology at the Indiana University School of Medicine and a researcher at the IU Simon Cancer Center. In his new position, Dr. Pili also will direct the genitourinary research program at the cancer center. In addition, Dr. Pili will serve as the medical director of the genitourinary clinical program at the IU Health Simon Cancer Center. more...
Research Highlights
NCI Announces Large-Scale Precision Medicine Trial, NCI-MATCH
National Cancer Institute
The National Cancer Institute (NCI) has announced a new precision medicine trial called NCI-MATCH (Molecular Analysis for Therapy Choice) that will be open for patient enrollment in July. The NCI-MATCH trial is the largest trial in the U.S. that will use precision medicine based on genetic screening of tumors. more...
Early Use of Palliative Care in Cancer Improves Patients’ Lives, Outcomes for Caregivers
Dartmouth-Hitchcock Norris Cotton Cancer Center
A new randomized clinical trial with Dartmouth investigators Kathleen Lyons, ScD, Tor Tosteson, ScD, Zhigang Li, PhD, and collaborators has noted significant improvement in several measures among those who began palliative care early. Their findings are described in, "Early Versus Delayed Initiation of Concurrent Palliative Care Oncology: Patient Outcomes in the ENABLE III Randomized Controlled Trial," published recently in the Journal of Clinical Oncology. more...
A MicroRNA May Provide Therapy Against Pancreatic Cancer
Melvin and Bren Simon Cancer Center, Indiana University
Indiana University cancer researchers found that a particular microRNA may be a potent therapeutic agent against pancreatic cancer. The research was published June 22 in the journal Scientific Reports. Led by Janaiah Kota, PhD, a researcher at the Indiana University Melvin and Bren Simon Cancer Center, the researchers found that restoring missing microRNA-29 in pancreatic cancer stromal cells reduced the viability and growth of the cancerous cells. more...
First Patient Treated with KTE-C19 in Non-Hodgkin's Lymphoma Trial
Moffitt Cancer Center
Moffitt Cancer Center has treated the first patient nationally in Kite Pharma's Phase 1/2 clinical trial of KTE-C19. The trial includes an investigational therapy for patients with refractory aggressive non-Hodgkin's lymphoma. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Frederick L. Locke, MD, is the trial investigator. more...
Rabbit Virus Improves Bone Marrow Transplants, Kills Some Cancer Cells
UF Health Cancer Center
University of Florida Health researchers have discovered that the myxoma virus, found in rabbits can kill some kinds of cancer cells while eliminating a common and dangerous complication of bone marrow transplants. The virus could be especially helpful to patients who have recurring cancer but cannot find a suitable bone marrow donor. more...
New Approach to Classifying Brain Tumors Could Lead to Significant Improvements in Diagnosis, Treatment
Case Comprehensive Cancer Center, Case Western Reserve University
Andrew Sloan, MD, a Case Comprehensive Cancer Center brain surgeon and neurosurgery professor at CWRU is among the primary authors of a new approach to classifying tumors that could lead to significant improvements in their diagnosis and treatment. Scientists and physicians from Cleveland and 43 other federally designated cancer centers used molecular and genetic analysis to develop an approach that reduces the role of individual observers’ assessments of the tumors’ appearance. Co-authors on the study include Cancer Center members Gene Barnett, MD, and Jill Barnholtz-Sloan, PhD. more...
Team Improves Data Reporting of Meningioma Treatment Outcomes Nationwide
VCU Massey Cancer Center
A new study led by VCU Massey Cancer Center physician-researcher Leland Rogers, MD, found that clinical trials to treat the most common primary brain tumor, meningioma, lack uniform guidelines for how physicians should determine whether treatment is effective at shrinking the tumor. A group known as RANO (Response Assessment in Neuro-Oncology) has created guidelines, in frequent use, for other central nervous system tumors. Dr. Rogers led a global team of radiation oncologists, neurologists, neuro-oncologists and neurosurgeons who sought to lay the groundwork for RANO to improve and standardize meningioma clinical trials. more...
Molecule Discovered that Speeds Tissue Regeneration After Bone Marrow Transplants
Simmons Cancer Center, UT Southwestern Medical Center
A joint investigation including UT Southwestern Medical Center has found a molecule that may play a significant role in accelerating cell recovery following bone marrow transplants, liver disease, and colon disease. The collaborative effort by UT Southwestern, Case Western Reserve University, and the University of Kentucky identified an enzyme named 15-PGDH that regulates tissue regeneration in multiple organs. By blocking 15-PGDH in mice with the newly discovered molecule, SW033291, the researchers found that they can rescue damaged bone marrow, liver tissue, and colon tissue. Tissue regeneration is important to recovery from injury, disease, and certain medical treatments. more...
Single-Dose HPV Vaccine Could Prevent Most Cervical Cancers
University of New Mexico Cancer Center
A research paper published in The Lancet Oncology showed that a single dose of the bi-valent human papillomavirus vaccine Cervarix® may prevent HPV-related cervical cancer. The paper presented data from two clinical trials, one sponsored by the National Cancer Institute and the other sponsored by GlaxoSmith Kline. The authors of the paper include Cosette Wheeler, PhD, The Victor and Ruby Hansen Surface Chair in Translational Medicine and Public Health Sciences and the Special Populations Staff Investigator at the UNM Cancer Center. more...
ALK1 Protein May Play a Role in Breast Cancer Metastasis
American Association for Cancer Research (AACR)
Breast cancer patients with high levels of the protein activin-like receptor kinase (ALK1) in the blood vessels of their tumors were more likely to develop metastatic disease, according to a study published in Cancer Research, a journal of the American Association for Cancer Research. This makes inhibition of the ALK1 pathway a possible new target for the treatment of metastatic breast cancer. Kristian Pietras, PhD, was the study's lead author. more...
Establishing Definitions to Increase Survival After Blood/Marrow Transplant
Roswell Park Cancer Institute
Blood and Marrow Transplantation (BMT) is a potentially curative treatment for patients with leukemia or other life-threating blood diseases. With a goal of increasing survival rates, a research team led by Roswell Park Cancer Institute investigators verified patient outcome data submitted by more than 150 U.S. transplant centers over an 11-year period to the Center for International Blood and Marrow Transplant Research. The results of this genome-wide association study led to the development of a first-of-its-kind definition of specific causes of mortality after unrelated-donor, or allogeneic, BMT. more...
Scientists Find Way to Disrupt Brain Tumor Stem Cells
Siteman Cancer Center
Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return. The ability of many brain tumors to regenerate can be traced to cancer stem cells that evade treatment and spur the growth of new tumor cells. But some brain tumor stem cells may have an Achilles' heel, researchers at Washington University School of Medicine in St. Louis have found. Albert H. Kim, MD, PhD, was senior author on the study. more...
Nationwide Clinical Trial Could Affect Older MDS Patients' Access to Bone Marrow Transplants
University of Kansas Cancer Center
Bone marrow transplants haven't always been available to those who often get myelodysplastic syndrome (MDS) - the elderly. Older people typically have other diseases besides MDS, and the risks and side effects associated with transplants are seen as too risky. To figure out the best treatment for this population, The University of Kansas Cancer Center's Bone Marrow Transplant program is participating in a nationwide clinical trial that analyzes outcomes after two common treatments: bone marrow transplant and chemotherapy. The results could lead to wider access to transplants. more...
Dartmouth Researchers Engineer Drug Micro-factory to Attack Tumor
Dartmouth-Hitchcock Norris Cotton Cancer Center
Attacking the perennial problem of systemic toxicity from typical chemotherapy treatments, Dartmouth investigators, led by Barjor Gimi, PhD, have engineered therapeutic cells encapsulated in nanoporous capsules to secrete antitumor molecules from within the tumor. Their findings are reported in, "Magnetic nanoparticle hyperthermia induced cytosine deaminase expression in microencapsulated E. coli for enzyme-prodrug therapy," in Journal of Biotechnology. more...
Discovery May Lead to Targeted Melanoma Therapies
Mount Sinai Health System Tisch Cancer Institute
Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a study led by researchers at Icahn School of Medicine at Mount Sinai. The research team found that the protein, called H2A.Z.2, promotes the abnormal growth seen in melanoma cells as they develop into difficult-to-treat tumors. H2A.Z.2 is part of the chromosome structure that packages genes, and has the ability to switch them on and off. Having high levels of this protein aberrantly activates growth-promoting genes in melanoma cells. more...
Disrupting Cancer Pathway Could Enhance New Immunotherapies
The University of Chicago Medicine Comprehensive Cancer Center
Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients. Researchers from the University of Chicago have shown how these tumors shield themselves from T cells -- the immune system’s front-line anti-cancer weapon -- by producing high levels of beta-catenin, an intracellular messenger. They show how beta-catenin prevents T cell invasion and undermines treatment. They also suggest ways to circumvent this roadblock. Thomas Gajewski, MD, PhD, was the study’s author. more...
New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment
UC San Diego Moores Cancer Center
Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients. The results revealed two genes that could help physicians make more informed treatment decisions for patients with this disease. more...
New Study Discovers Potential Target for Tissue Regeneration
UK Markey Cancer Center
A new study co-led by Hsin-Hsiung Tai, PhD, professor of pharmaceutical sciences at the University of Kentucky, suggests that a key prostaglandin (PG) metabolic enzyme shows promise as a drug target to help tissue regeneration and repair, particularly after bone marrow transplantation and tissue injuries. The study looked at the role of 15-PGDH, an enzyme that quickly degrades a bioactive lipid called PGE2, in tissue regeneration in mouse models. more...
Miniature Device Could Unlock the Promise of Some Kidney Cancer Drugs
Memorial Sloan Kettering Cancer Center
Inspired by a surprise discovery, Memorial Sloan Kettering scientists have engineered a tiny particle that could make it possible to deliver drugs directly to the kidneys and minimize their uptake in other organs. The device, called a mesoscale nanoparticle, could help boost the usefulness of some kidney cancer drugs and might also be used in the treatment and diagnosis of other kidney conditions. more...
Weight Loss, Vitamin D Reduce Inflammation Linked to Cancer
Fred Hutchinson Cancer Research Center
For the first time, researchers at Fred Hutchinson Cancer Research Center have found that weight loss, in combination with vitamin D supplementation, has a greater effect on reducing chronic inflammation than weight loss alone. Chronic inflammation is known to contribute to the development and progression of several diseases, including some cancers. more...
Study Supports IDH Gene as Prognostic Marker in Anaplastic Astrocytoma
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

New findings suggest that a gene called IDH might be a prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH. The IDH study was done as part of the phase III clinical trial RTOG 9813, which involved 301 patients with anaplastic astrocytoma. The duel-arm trial evaluated the effectiveness of radiation therapy plus either of two chemotherapy drugs: temozolomide and nitrosourea. more...
Mechanism Leading to BRAF Inhibitor Resistance in Melanoma Patients Discovered
Moffitt Cancer Center
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant. Moffitt Cancer Center researchers have discovered a novel mechanism that can lead melanoma cells to develop resistance to drugs that target the protein BRAF. more...
Discovery Could Lead to Personalized Colon Cancer Treatment Approach
UNC Lineberger Comprehensive Cancer Center
A UNC Lineberger Comprehensive Cancer Center discovery of just how a certain tumor suppressor molecule works to prevent tumor growth could lead to a new personalized treatment approach for colon cancer. Researchers have reported that the tumor-suppressing protein AIM2, or Absent in Melanoma 2, helps prevent colon cancer by restricting a signaling molecule called Akt. With this finding, the researchers believe they've found a possible drug target for colon cancer patients who lack the tumor suppressor AIM2. more...
Researchers Identify Patients At Risk for Stem Cell Transplant Complications
VCU Massey Cancer Center
Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival. This first-of-its-kind research continues the efforts of principal investigator Amir Toor, MD, to understand the immune system as a dynamical system that can be modeled to improve stem cell transplantation. more...
Portable Finger-Probe Device Can Measure Liver Function in Potential Organ Donors
Jonsson Comprehensive Cancer Center, UCLA
A portable, finger-probe device successfully measured liver function in brain dead adult organ donors, a finding that could change the way organs are assessed and save thousands of dollars per transplant, a UCLA study has found. more...
"Boosted" Radiation Dose May Make Some Pancreatic Cancers Resectable
Fox Chase Cancer Center, Temple Health
Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more difficult and sometimes impossible. Researchers at Fox Chase Cancer Center have identified a way to safely shrink the tumor, pulling it away from these vessels and allowing patients to undergo potentially curative surgery. more...
Boosting Gut Bacteria Defense System May Improve Treatments for Bloodstream Infections
Simmons Cancer Center, UT Southwestern Medical Center
An upset in the body's natural balance of gut bacteria that may lead to life-threatening bloodstream infections can be reversed by enhancing a specific immune defense response, UT Southwestern Medical Center researchers have found. In the study, scientists identified how a certain transcription factor - a protein that that turns genes on and off - works in partnership with a naturally occurring antibiotic to kill infection-causing fungi called Candida albicans. Andrew Koh, MD, was senior author on the study. more...
New Discovery Could Explain How Prostate Cancer Becomes Lethal
University of New Mexico Cancer Center
Wadih Arap, MD, PhD, Richard Lauer, MD, FACP, and Renata Pasqualini, PhD, at the UNM Cancer Center are among the authors of the research paper published in the Proceedings of the National Academy of Sciences that has uncovered an unprecedented mechanism for developing cancer. The multidisciplinary team identified two new key players in the development of prostate cancer, PCA3 and PRUNE2, which come from the same location in the genome and physically interact to regulate each other's activity. more...
Cancer Blocked by Halving Levels of Protein Thought To Be 'Untouchable'
UCSF Helen Diller Family Comprehensive Cancer Center
In a surprising finding, a team of UC San Francisco and Stanford University scientists has discovered that a protein thought to be crucial for the body to develop and function correctly can be reduced by half in mice with no apparent ill effects. More strikingly, the group found that the full complement of the protein normally found in cells can be hijacked by cancer cells to fuel their growth. more...
New Drug Stimulates Tissue Regeneration, Catalyzing Faster Regrowth and Healing
Case Comprehensive Cancer Center, Case Western Reserve University
In a new study published in Science, researchers at Case Western Reserve and UT Southwestern Medical Center detail how a new drug repaired damage to the colon, liver and bone marrow in animal models - even going so far as to save the lives of mice who otherwise would have died in a bone marrow transplantation model. more...
Study Finds Significant Drop in New Prostate Cancer Diagnoses
Vanderbilt-Ingram Cancer Center
A study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men. The new research was led by Daniel Barocas, MD, MPH. more...
Study Adds Diabetes Drug with Anti-Cancer Effect to Ovarian Cancer Treatment
The University of Chicago Medicine Comprehensive Cancer Center
Recent studies have suggested that metformin, an established drug developed to treat patients with type II diabetes, may provide significant benefits, including increased survival, to patients being treated for advanced cancers. The University of Chicago Medicine is leading, with two other centers, a clinical trial that will compare the most effective current therapy for patients with stage 3 or stage 4 ovarian cancer against that same therapy plus metformin. To enroll in the trial, volunteers must have a presumed or confirmed diagnosis of ovarian, fallopian tube, or primary peritoneal carcinoma, but not diabetes. more...
Healthy Diet Linked to Lower Death Rates Among Low-Income Residents in SE U.S.
Vanderbilt-Ingram Cancer Center
Eating a healthy diet was linked with a lower risk of dying from heart disease, stroke, cancer or other diseases among a population of low-income individuals living in the Southeastern U.S., according to research led by Vanderbilt University investigators. Nearly two-thirds of the participants in the study were African-American. more...
Fatalistic Beliefs May Prevent Appalachian Women from Completing HPV Vaccination
UK Markey Cancer Center
Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women. more...
Other News
UNC Lineberger Reports Passing of Michael O'Malley
UNC Lineberger Comprehensive Cancer Center
Michael O'Malley, PhD, 64, died unexpectedly on June 24 at his home in Chapel Hill, NC. Dr. O'Malley had recently retired as associate director, UNC Lineberger Comprehensive Cancer Center, after more than 30 years of service to the state of North Carolina. He also served as an adjunct associate professor of health policy and management at the UNC Gillings School of Global Public Health, and co-directed the Cancer Control Education Program, an NCI-funded pre- and post-doctoral training program in cancer prevention and control. In his memory, please consider donating to the Michael S. O'Malley Cancer Prevention Fund at the UNC Lineberger Comprehensive Cancer Center. more...
Nobel Laureate and Scientist Rose Remembered
Fox Chase Cancer Center, Temple Health
Scientist and Nobel Laureate Irwin "Ernie" Rose, PhD, passed away June 2, 2015, after a long illness. He was 88. Dr. Rose shared the 2004 Nobel Prize for chemistry with Aaron Ciechanover and Avram Hershko of the Israel Institute of Technology for their pioneering work in discovering the ubiquitin conjugating system. Dr. Rose conducted this research as a senior scientist at Fox Chase Cancer Center in Philadelphia, where he worked from 1963 until he retired in 1995. more...
Abstracts Sought for Molecular Targets and Cancer Therapeutics Conference
American Association for Cancer Research (AACR)
The 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference will bring together an estimated 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology. View the current program online and make plans to submit an abstract of your latest research by the August 4 deadline. more...
CCSS Career Development Award Announcement
Comprehensive Cancer Center St. Jude Childrens Research Hospital
The Childhood Cancer Survivor Study (CCSS) Career Development Award is designed to create an opportunity for early career investigators and trainees with an interest and aptitude in childhood cancer survivorship research to develop and complete an initial research study within the CCSS. This will serve as a foundation for the development of a career path that includes survivorship research. Applications for the 2016 award are due October 1, 2015. more...
Job Opportunities
Vice President, Development  
The Wistar Institute


Faculty Positions in Cancer Prevention and Control  
University of Colorado Cancer Center and Colorado School of Public Health (CSPH)
University of Colorado Anschutz Medical Campus


Program Leader for Cancer Prevention and Control
Tenure Track Associate or Full Professor  
University of Colorado Cancer Center and Colorado School of Public Health (CSPH)
University of Colorado Anschutz Medical Campus


Meeting Announcements

7th Annual AACI Clinical Research Initiative Meeting

Register now:
July 8-9, 2015
The Westin O'Hare, Rosemont, IL

2015 Rally for Medical Research Hill Day

Register now:
September 16-17, 2015
Washington, DC

3rd Annual AACI Physician Clinical Leadership Initiative Meeting

Save the date for the 3rd Annual AACI Physician Clinical Leadership Initiative Meeting in Washington DC, at the Mandarin Oriental, on Sunday, October 25, 2015 from 4:00-6:00 PM, EST. More information about AACI PCLI go to
Register now:

2015 AACI/CCAF Annual Meeting

Register now:
October 25-27, 2015
Mandarin Oriental, Washington, DC